A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: CNTO 1959Drug: Placebo
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 24
- Registration Number
- NCT01484587
Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 102
- Registration Number
- NCT01478633
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: JNS002
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2013-07-04
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 3
- Registration Number
- NCT01371227
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 79
- Registration Number
- NCT01366638
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
Phase 3
Completed
- Conditions
- Attention-Deficit / Hyperactivity Disorder
- Interventions
- Drug: JNS001
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 253
- Registration Number
- NCT01357993
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
Phase 3
Completed
- Conditions
- Attention-Deficit Hyperactivity Disorder
- Interventions
- Drug: JNS001Drug: Placebo
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 284
- Registration Number
- NCT01323192
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 100
- Registration Number
- NCT01309386
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 9
- Registration Number
- NCT01309412
An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 323
- Registration Number
- NCT01299389
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 183
- Registration Number
- NCT01292239
© Copyright 2025. All Rights Reserved by MedPath